affect of felodipine against CsA-induced nephrotoxicity in these patients is suggested. Background. Due to their vasodilatory effect, calcium antagonist may have a renoprotective against cyclosporin (CsA)-induced nephrotoxicity and rise in blood Key words: cyclosporin; felodipine; glomerular filtrapressure (BP) seen in renal transplantation. tion rate; hypertension; renal plasma flow; renal Methods. In order to evaluate the effect of the calcium transplant antagonist felodipine on renal function and BP during cyclosporin treatment, 79 CsA-treated renal transplant recipients were investigated during the first 3 months after transplantation in a randomized, double-blind,
. Study course and disposition of 99 cyclosporin-treated mechanisms involved. The patients were investigated renal transplant recipients randomly allocated to treatment with during the first 3 months after transplantation using a either felodipine 10 mg once daily or placebo during the first 3 randomized, double-blind, placebo-controlled design months after transplantation with two parallel groups. The effect of a once daily administered dose of the dihydropyridine calcium ant- aldosterone (Aldo), atrial natriuretic peptide (ANP)
Adverse eventsa 6 8 and arginine vasopressin (AVP), and (iv) BP and pulse
Refusal to cooperate 3 1 rate was assessed at 6 and 12 weeks after transplanta-Patients assessable at week 6 39 40
tion. Furthermore, comparisons between the treatment Patients included in analysis of renal 31 30 function at week 6 groups were intended with regard to plasma creatinine Incomplete urinary bladder 2 4 on day 7 and week 6 and 12 post-transplant, length of emptying post-transplant hospitalization time, duration of primData not obtainable 6 6 ary anuria, and number of rejection episodes.
Patients discontinued between week 6 9 8 and week 12 Adverse eventsa 7 6 Patients and methods 
Patients
Patients included in analysis of renal 27 24 function at week 12 Ninety nine consecutively transplanted renal recipients willIncomplete urinary bladder 2 7 ing to participate and fulfilling the inclusion and exclusion emptying criteria were enrolled in the study. The inclusion criteria were
Data not obtainable 1 1 (i) males or females aged between 18 and 70 years, and (ii) renal transplant recipients treated with CsA. The exclu-aAll adverse events were considered not study related. Four deaths sion criteria were (i) heart failure, (ii) previous cerebrovascu-occurred, all in the placebo group. No other major differences lar insult, (iii) contraindications to calcium antagonists, and between the groups were observed.
(iv) childbearing potential. The disposition and course of the patients included are given in Table 1 . The final group of with either felodipine ER tablets 10 mg 1 h prior to transplantation and once daily during the study period, given in the morning, or placebo. Compliance was assessed by tablet counting during and at the end of the study. a.m. until the end of the examination. The patients took their usual immunosuppressive and antihypertensive medicaExamination of renal function and BP and heart rate was performed twice, i.e. at 4-6 weeks and at 10-12 weeks after tion and the study drug at 7 a.m. The patients arrived at the laboratory at 8 a.m. and were in the supine position except renal transplantation. The procedures on the two investigational days were identical. At 10 p.m. on the day before during voiding. No bladder catheterization was performed.
Two indwelling catheters ( Venflon), one in each arm, were the study, 300 mg of lithium carbonate was given orally. On the day of the investigation, after a 7 h fast, an oral water inserted for administration of the radiolabelled tracers and blood sampling, respectively. From 10 a.m., urine was load of 200 ml of tap water was given every 30 min from 7 and AVP) were determined by slight modifications of RIAs and diastolic BP and heart rate were used.
previously described [16] [17] [18] [19] . During the study period, patients were treated according Sodium in plasma and urine was measured by routine to standard regimens in the Department of Medicine and methods in the Department of Clinical Chemistry, Skejby Nephrology C, Skejby Hospital, with regard to immunosupHospital. pression (CsA, prednisolone, azathioprine) and antihyperPlasma and urinary concentrations of lithium were meastensive therapy [ furosemide, metoprolol, pinacidil (a ured by atomic absorption spectrophotometry. potassium channel opener)]. In cases of primary functioning BP was measured after 30 min in the supine position with graft, doses of CsA were 5 mg/kg/day for 2 days, followed a Hawksley Random Zero Sphygmomanometer ( UK ). If an by 10 mg/kg/day until day 30, whereafter the dose gradually initial comparison with an automatic device ( Takeda tapered with 2 mg/kg/day to 5-7 mg/kg/day for the remainMedical, Japan) was satisfactory with a deviation of the der of the study period. In cases of primary graft diastolic BP <10 mmHg, this equipment was used for further anuria induction, treatment with Minnesota anti-lymphocyte measurements. globulin or anti-human-T-lymphocyte globulin was given.
All clearances were corrected for body surface area and Treatment with CsA was initiated after 5 days if graft expressed per 1.73 m2. The comparisons of the renal function function was achieved, or after 10 days if anuria persisted.
parameters and the BP and heart rate variables between the Whole blood trough concentrations of CsA of 200-300 ng/ml two groups were performed using Student's two-sample tduring the first month decreasing to 150-250 ng/ml thereafter test. The comparison of hospitalization time between the two were aimed at. Acute rejection episodes resistant to bolus groups was performed using the Mann-Whitney test due to infusions of methylprednisolone were treated with a monolack of normal distribution. Frequencies were compared clonal antibody preparation (Orthoclone OKT-3).
using a two-sided x2 test. Unless otherwise specified, results are presented as means±standard deviations (SD). was significantly higher (20%) in the felodipine Based on the assumption that the lithium ion is reabsorbed group (RPF: placebo: 182±56 ml/min; felodipine: solely in the proximal tubules in approximately the same 219±69 ml/min; P=0.03) compared with placebo. No proportions as sodium and water, the clearance of lithium differences were found in GFR (GFR: placebo:
Methods

Results
GFR
), calculated as the ratio between urinary excretion rate 37±17 ml/min; felodipine: 42±16 ml/min) or filtration of lithium and the interpolated mean plasma concentration, fraction (FF: placebo: 20±5%; felodipine: 19±5%).
is thought to give an estimate of the delivery of isotonic fluid At 12 weeks after transplantation, both RPF from the proximal tubules into the thin segment of Henle and GFR were significantly higher (28 and 23%, [15] . Accepting these assumptions and by use of GFR, C Li , clearance of sodium (C Na ), urine flow ( V ) and plasma and respectively) in the felodipine group (RPF: urine concentrations of sodium (P Na and U Na ), the following placebo: 175±48 ml/min; felodipine: 225±77 ml/min; calculations give estimates of the renal handling of sodium P<0.01. GFR: placebo: 40±16 ml/min; felodipine:
in the proximal and distal segments:
49±18 ml/min; P=0.05) compared with placebo. No Proximal absolute reabsorption of sodium (PAR Na )= difference in filtration fraction was found between the
two treatments ( FF: placebo: 22±4%; felodipine: 22±4%).
Proximal fractional reabsorption of sodium and water (PFR Na/water )=(1−C Li /GFR)×100%
Tubular function
Distal absolute reabsorption of sodium (DAR Na
Clearance of lithium (C Li ), fractional excretion of lithium (FE Li ), fractional sodium excretion (FE Na ),
Distal fractional reabsorption of sodium (DFR Na
urinary sodium excretion ( U Na V ), proximal fractional At 6 weeks after transplantation, no differences between the treatment groups were found in any of the parameters concerning tubular sodium handling and urinary sodium excretion.
At 12 weeks after transplantation, a higher C Li (P<0.05) and a higher DAR Na (P<0.05) were found in the felodipine group. There was a tendency towards a higher overall sodium excretion after felodipine, but the difference was not significant (P=0.09).
Hormonal parameters
Plasma levels of AngII, Aldo, ANP and AVP are given in Table 4 .
Significantly higher plasma levels of Aldo (P<0.05) and of AngII (P=0.01) in the felodipine group were found at 6 weeks after transplantation, whereas no difference was observed in plasma concentrations of ANP or AVP, or in any of the hormonal parameters at 12 weeks after transplantation.
Blood pressure and heart rate
Both systolic and diastolic BP were significantly lower in the felodipine group, both at 6 weeks (placebo: 149/89±14/8 mmHg; felodipine: 130/77±17/9 mmHg; P<0.001) and at 12 weeks after transplantation (placebo: 144/84±22/12 mmHg; felodipine: 131/78± 16/8 mmHg; P<0.05). Heart rate was significantly higher after felodipine both at 6 weeks (placebo: 72±12 beats/min; felodipine: 85±15 beats/min; P< 0.001) and at 12 weeks after transplantation (placebo: 70±10 beats/min; felodipine: 81±10 beats/min; Median length of hospitalization was 18 days (range 8-51) in the felodipine group (n=39) and 13 days (range 7-44) in the placebo group (n=40). Median and absolute reabsorption of sodium (PFR and PAR Na ), and distal fractional and absolute reabsorp-duration of primary anuria was 9 days (range 1-21) in the felodipine group (n=10) and 3 days (range tion of sodium (DFR Na and DAR Na ) are given in Table 3 .
1-20) in the placebo group (n=12). The average Table 3 . Clearance of lithium (C Li ), fractional excretion of lithium (FE Li ), fractional sodium excretion (FE Na ), urinary sodium excretion ( U Na V ), proximal fractional and absolute reabsorption of sodium (PFR and PAR Na ), and distal fractional and absolute reabsorption of sodium (DFR Na and DAR Na ) at 6 and 12 weeks after transplantation in cyclosporin-treated renal transplant recipients randomly allocated to treatment with felodipine or placebo; mean±SD 6 weeks 12 weeks Significant deviation between placebo and felodipine group: *P<0.05. number of rejection episodes was 0.69 (range 0-3) in Discussion the felodipine group (n=39) and 0.65 (range 0-3) in the placebo group (n=40). At day 7 post-transplant, Experimental and animal studies have indicated a 16 patients underwent dialysis (six patients in the protective role of calcium channel blockers including placebo group and 10 patients in the felodipine group), dihydropyridines against the nephrotoxic effects of while 63 patients had functioning grafts. CsA [7] [8] [9] 20] . Also in humans, calcium antagonists No statistically significant differences between the may exert a preventive role against CsA-induced groups were found in length of hospitalization time or nephrotoxicity. It was shown by Wagner and in numbers of rejection episodes. Statistical analysis of Neumayer that post-transplant acute tubular necrosis duration of primary anuria was not possible due to and delayed renal graft function after transplantation the small numbers of patients. No difference was was prevented by diltiazem [11] . More long-term observed in plasma creatinine at day 7 after trans-observations supporting a beneficial effect of diltiazem plantation in patients with functioning grafts The present prospective study shows an improving mmol/l (n=24); felodipine: 137 (80-354) mmol/l (n= effect of felodipine ER 10 mg o.m. on renal haemo-27); medians with ranges] in the patients assessable for dynamics in CsA-treated renal transplant recipients renal function.
both at 6 and 12 weeks after transplantation, in accordance with a previous acute study in stable renal Cyclosporin and antihypertensive treatment transplant recipients [10] . Our results are in agreement with previous studies of other dihydropyridines in the The daily dose of CsA given at 6 weeks after transearly post-transplant period as well as in stable renal plantation was the same in the placebo group graft recipients [14, 26 ] . Whether calcium antagonist (7.0±1.5 mg/kg/day) and in the felodipine group exert a specific counteraction against CsA-induced (6.9±2.2 mg/kg/day) as well as at 12 weeks after renal vasoconstriction is not clear from our study, transplantation, 5.5±1.2 mg/kg/day in the placebo since we did not evaluate the effects of felodipine in group and 5.8±0.9 mg/kg/day in the felodipine group.
patients not treated with CsA. Similar effects of felodipThe results of routine clinical measurements of CsA ine have been demonstrated in both healthy volunteers trough concentrations were 264±115 ng/ml in the feloand hypertensive patients [2] [3] [4] [5] [6] . We found no effect of dipine group and 285±129 ng/ml in the placebo group felodipine on plasma creatinine level day 7, number of at~5 weeks after transplantation, and 229±76 ng/ml rejection episodes or duration of hospitalization time in the felodipine group and 196±107 ng/ml in the after transplantation. Although data on duration of placebo group at 11 weeks after transplantation. No primary anuria could not be analysed due to the small statistically significant differences between the groups number of patients, felodipine did not seem to improve were found. this parameter when looking at the median values. In Doses and numbers of patients receiving concomitcontrast, Morales et al. reported a lower plasma creatiant antihypertensive treatment are given in Table 5 . A nine level and a shorter renal function recovery and significantly greater number of patients in the placebo hospitalization time 1 month after renal transplantagroup were treated with furosemide and metoprolol at tion in CsA-treated patients given nifedipine, initiated both 6 and 12 weeks after transplantation compared preoperatively [12] . Interestingly, when adjusting CsA with the felodipine group, and more patients in the doses to obtain equal whole blood trough levels in placebo group were treated with pinacidil 12 weeks after transplantation.
diltiazem-treated patients and in a control group, Wahlberg et al. did not find any significant benefit in patients treated with CsA [28] . The rather extensive daily sodium excretion observed in both treatment either ischaemic protection or in reducing the number of rejections [22] , and found no difference in creatinine groups may reflect the concomitant treatment with furosemide in combination with a felodipine-induced clearance at 2 weeks and at 3 months after transplantation. Whether the reduction of the number of rejection higher natriuresis in the felodipine group. We found no evidence of a direct role of vasoactive peptides in episodes after diltiazem reported by Wagner and Neumayer is a result of the probably stronger immuno-CsA-induced renal vasoconstriction. The reason for a higher plasma level of AngII and Aldo in the felodipine suppression induced by the higher CsA blood levels or represents an intrinsic immunological effect of this group at 12 weeks after transplantation is not clear.
Felodipine caused a rise in GFR and RPF despite a drug is not known. In vitro, diltiazem has been shown to exhibit a dose-related suppression of lymphocyte concomitant significantly lowering of BP. A strict BP control in renal transplant recipients is an important proliferation [27] .
In the present study, treatment with felodipine was factor for renal graft prognosis [29] . Our results indicate that dihydropyridines may be especially advantainitiated preoperatively to the recipients, while addition of felodipine to the kidney preservation perfusion fluid geous in the handling of hypertension in CsA-treated renal transplant recipients, in theory due to their renal was not performed. Wagner and Neumayer reported an improvement on renal function when administering vasodilatory and natriuretic effects. Concerns could be raised as to whether the preferential dilatation by diltiazem also to the harvested kidneys [11] , suggesting an effect on ischaemia reperfusion renal lesions. The calcium antagonists of afferent arterioles in the long term would harm the kidney by favouring an increase role of this combined treatment has not yet been clarified for the dihydropyridines.
in glomerular capillary pressure. However, the glomerular capillary pressure depends on both the renal Despite the significant differences in renal haemodynamics determined experimentally, our present study vascular resistance and on the systemic BP. Thus, a theoretical increase in glomerular capillary pressure showed no difference in plasma creatinine in the same patients at 6 and 12 weeks after transplantation. This may be antagonized by the observed concomitant lowering of the arterial BP. finding stresses the need of precise and reliable methods for assessment of renal function. Thus, results based Both CsA and dihydropyridine calcium antagonists are metabolized via the hepatic cytochrome P-450 only on measurements of plasma creatinine should be interpreted with caution.
IIIA4 enzyme [30, 31] . Some reports indicate that dihydropyridines, like isradipine and amlodipine, in conIn our previous acute study, we found a significantly higher natriuresis and urinary output after a single trast to verapamil and diltiazem, do not interfere with CsA pharmacology [32, 33] . On the other hand, condose of felodipine 10 mg [10] . The present study shows no major effect on renal sodium handling after pro-flicting results have been presented with regard to nifedipine [34, 35] , and nicardipine has been shown to longed treatment with felodipine, although there is a tendency to a higher overall sodium excretion after augment plasma CsA in renal transplant recipients [36 ] . Due to protocol limitations, trough levels of felodipine at 12 weeks after transplantation. The negative sodium balance induced by felodipine is also cyclosporin were not obtainable on the experimental days in our study. However, treatment with felodipine maintained after continued treatment despite involvement of physiological counter-regulatory mechanisms for 6 or 12 weeks did not affect the treatment doses of CsA in renal transplant recipients treated after a stand- [5] . Although there seems to be a discrepancy between the acute and chronic effect of felodipine on sodium ard regimen involving whole blood CsA trough level measurements, supporting the evidence that dihyexcretion in our two studies in renal transplant recipients, the fact that there is a higher frequency of dropyridines do not influence CsA pharmacokinetics.
Although there seems to be a preventive effect of concomitant treatment with a loop diuretic in the placebo group gives indirect evidence for a persistent calcium channel blockers including felodipine against the CsA-induced decline in renal graft function in the natriuretic effect of felodipine also in the present study, in agreement with a previous study in dermatological early post-transplant period, it is not clear whether 
